Treatment of relapsed aggressive lymphomas: Regimens with and without high-dose therapy and stem cell rescue

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 49, Issue 7, 2002, Pages

  Hagemeister, Fredrick B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Aggressive lymphoma; Ifosfamide; Relapse therapy; Stem cell rescue

Indexed keywords

BETA 2 MICROGLOBULIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; PACLITAXEL; PLATINUM; PREDNISONE; RITUXIMAB; TOPOTECAN; VINCRISTINE;

AREA UNDER THE CURVE; BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LYMPHOMA; MIDDLE AGED; PREDNISONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; VINCRISTINE;

EID: 0036256650     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy-regimens for advanced non-Hodgkin's lymphoma
2. A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project
3. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma
4. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial
5. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels
6. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the "tumor score"
7. Gallium scan result second or more cycles of chemotherapy correlates with clinical outcome in aggressive good prognosis NHL treated with CHOP containing regimen
8. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma
9. 18F]FDG-PET a valid alternative to conventional diagnostic methods?
10. 14 Day CHOP in patients with aggressive non-Hodgkin's lymphoma (NHL): Preliminary results
11. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma (NHL). Japan Clinical Oncology Group (JCOG) Study 9505
12. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity
13. CHOEP (CHOP+etoposide): The new standard regimen for younger patients with low risk (low LDH) aggressive non-Hodgkin's lymphoma (NHL)
14. 2-Weekly CHOP (CHOP-14): The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age
15. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
16. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
17. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: The M.D. Anderson experience
18. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas
19. Three-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma
20. 2-microglobulin is capable of improving the prognostic discrimination of international index system (IIS)
21. Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma
22. High response rate and complete remission rate achieved by adding rituximab to Taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma
23. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients
24. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
25. Gemcitabine for relapsed or resistant lymphoma
26. The combination of gemcitabine plus vinorelbine as salvage treatment in non-Hodgkin's lymphoma. A Hellenic Cooperative Oncology Group study
27. Liposomal, vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
28. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
29. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma
30. Prognostic factors affecting the efficacy of rituximab plus CHOP (R-CHOP) therapy in elderly patients with di1use large B-cell lymphoma (DLCL): Results of a randomized GELA Trial
31. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL). Interim results of a Randomized GELA trial
32. Phase II study of dose-adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas
33. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma
34. Intensive reinduction with high-dose ifosfamide/VP-16 and ifosfamide/novantrone followed by BEAM and stem cell transplant for recurrent lymphoma (NHL)
35. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma
36. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors
37. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphomas
38. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model